[PPT] - Accessibility version: https://youtu.be/0ip5imNzLY4 PowerPoint Presentation

SLIDE 1

Accessibility version: https://youtu.be/0ip5imNzLY4

SLIDE 2





SLIDE 3








‒ ‒

SLIDE 4







‒

SLIDE 5




‒

‒ ‒

SLIDE 6

 



‒

SLIDE 7








SLIDE 8

1995-2011 NIS data available at: http://www.cdc.gov/vaccines/stats-surv/nis/default.htm#nis

Increased from 88% to 92% for Hispanic children Increased from 87% to 91% for Black children MMR coverage from 1995 to 2011 Remained at or above 91% for White children

SLIDE 9

http://www.cdc.gov/nchs/nis.htm

SLIDE 10

1989 – 2nd Dose recommended 1963 Vaccine licensed 1989 1991 Epidemic 1993 VFC 2000 Elimination declared

SLIDE 11

From 2007 2011, no significant coverage differences among these 3 groups

http://www.cdc.gov/nchs/nis.htm 1995 2011 NIS data available at: http://www.cdc.gov/vaccines/stats-surv/nis/default.htm#nis

Increased from 87% to 93% for Hispanic children Increased from 84% to 93% for Black children Polio coverage from 1995 to 2011 Increased from 89% to 93% for White children

SLIDE 12

Increased from 75% to 84% for Hispanic children Increased from 74% to 81% for Black children DTaP coverage from 1995 to 2011 Increased from 80% to 85% for White children

http://www.cdc.gov/nchs/nis.htm 1995 2011 NIS data available at: http://www.cdc.gov/vaccines/stats-surv/nis/default.htm#nis

SLIDE 13





SLIDE 14

 

SLIDE 15

SLIDE 16






SLIDE 17





SLIDE 18







SLIDE 19






SLIDE 20

NNDSS, National Notifiable Diseases Surveillance System MMWR 1999;48 (RR 12)

SLIDE 21

SLIDE 22

§ §

SLIDE 23



SLIDE 24



SLIDE 25

25 50 75 100

, ≥1 dose Ages 24–35 months

25 50 75 100

, ≥2 doses Ages 13–17 years

25 50 75 100

Nationally , ≥2 doses Ages 19–35 months

http://www.cdc.gov/nchs/nis.htm

SLIDE 26

SLIDE 27

25 50 75 100 Year

SLIDE 28

SLIDE 29



SLIDE 30





SLIDE 31

SLIDE 32





SLIDE 33

SLIDE 34






SLIDE 35

SLIDE 36




–

–

SLIDE 37

 





SLIDE 38






AN, Alaska Native

McMahon, BJ et al. Hepatology 2011;54:801–7

SLIDE 39

Incidence of Symptomatic Hepatitis B in Alaska Natives, 1981–2010

McMahon, BJ et al. Hepatology 2011;54:801–7

SLIDE 40





AN, Alaska Native

National Immunization Survey, http://www.cdc.gov/nchs/nis.htm McMahon, BJ et al. Hepatology 2011;54:801–7

SLIDE 41

McMahon, BJ et al. Hepatology 2011;54:801–7

SLIDE 42

McMahon, BJ et al. Hepatology 2011;54:801–7

SLIDE 43

SLIDE 44

 





SLIDE 45






–

– –

SLIDE 46

PRP-OMP vaccine introduced

Pediatrics 2006;118;e421-e429; doi: 10.1542/peds.2006-0287

Change in vaccine Return to PRP-OMP vaccine

SLIDE 47

–

SLIDE 48

SLIDE 49

 



SLIDE 50



NIS, National Immunization Survey, http://www.cdc.gov/nchs/nis.htm

–

SLIDE 51



SLIDE 52







SLIDE 53

SLIDE 54

 

SLIDE 55

 

SLIDE 56

  

–5

SLIDE 57

SLIDE 58

http://www.cdc.gov/nchs/nis.htm

SLIDE 59

  

SLIDE 60



SLIDE 61






SLIDE 62

   

SLIDE 63

Global Immunization 1980 010 Global Coverage of DTP3 at 85% in 2010

SLIDE 64

SLIDE 65

 

SLIDE 66

SLIDE 67

$0 $200 $400 $600 $800 $1,000 $1,200 $1,400 $1,600 $1,800 1990 2000 2012

HPV rotavirus hep A MCV Td/Tdap flu PCV13 varicella hep B Hib MMR polio DTaP

$176 $518 $1,712

2012 represents minimum cost to vaccinate a child (birth through 18); exceptions are 1) no preservative influenza vaccine, which is included for children 6–47 months of age, and 2) HPV for males and females Federal contract prices as of February 1, 1990, September 27, 2000, and April 24, 2012

Cost to Vaccinate One Child with Vaccines Universally Recommended from Birth through 18 Years of Age 1990, 2000, and 2012 Cost to Vaccinate One Child with Vaccines Universally Recommended from Birth through 18 Years of Age 1990, 2000, and 2012

SLIDE 68

*DTP/HepB/Hib

SLIDE 69

SLIDE 70

SLIDE 71

www.gavialliance.org

SLIDE 72

˗ ˗

SLIDE 73

SLIDE 74





 

SLIDE 75

SLIDE 76

   

SLIDE 77